$DYAI News
Last published 1d ago
- 1d agoDYAIDyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S.GlobeNewswireDyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented...
- 1w agoDYAIDyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026GlobeNewswireJUPITER, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a
- 3mo agoDYAIDyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private PlacementGlobeNewswireJUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) (the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions
- 3mo agoDYAIDyadic Second Quarter 2026 Conference Call - DYADIC INTERNATIONAL INCEarnings Call TranscriptsGood evening, and welcome to Dyadic International's Q2 2026 conference call. Currently, all participants are in the listen-only mode. Following management's prepared remarks, there will be a brief question-and-answer ses
- 3mo agoDYAIDyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business AreasGlobeNewswireJUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions, a
- 3mo agoDYAIDyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development AgreementGlobeNewswireJUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant
- 3mo agoDYAIDyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026GlobeNewswireJUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a
- 3mo agoDYAIDyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 DaysGlobeNewswireJUPITER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, today announced that, within approximately 15
- 3mo agoDYAIDyadic Announces Continued Listing on the Nasdaq Capital MarketGlobeNewswireJUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant
- 3mo agoDYAIDyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme ProgramGlobeNewswireJUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant
- 4mo agoDYAIGlobal Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial PotentialGlobeNewswireJUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the
- 4mo agoDYAIDyadic Expands IP Protection and Business Development Activities in JapanGlobeNewswireJUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the
- 4mo agoDYAIDyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial AdoptionGlobeNewswireJUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions ("Dyadic" or the "Company"), a biotechnology company focused on the development and
- 5mo agoDYAIDyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine DevelopmentGlobeNewswireJUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic," "we," "us," "our," or the "Company") (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the
- 5mo agoDYAIDyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026GlobeNewswireJUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing
- 5mo agoDYAISkyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ETGlobeNewswireNew York, NY, May 21, 2026 (GLOBE NEWSWIRE) -- Skyline Corporate Communications Group, LLC ("Skyline"), an investor relations and corporate communications firm headquartered in New York, today announced that Dyadic
- 5mo agoACUAIDXAZBSET+11Sidoti Events, LLC's May Micro-Cap Virtual ConferenceACCESS NewswireNEW YORK, NY / ACCESS Newswire / May 20, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Virtual Investor Conference
- 5mo agoDYAIDyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor ConferenceGlobeNewswireJUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic," "we," "us," "our," or the "Company") (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing
- 6mo agoDYAIDyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company ProgressGlobeNewswireReceived initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industryCommercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals
- 6mo agoDYAIDyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026GlobeNewswireJUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a
- 7mo agoDYAIDyadic Announces 2025 Financial Results and Highlights Recent Company ProgressGlobeNewswireCommercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExpanded
- 8mo agoDYAIDyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT BioservicesGlobeNewswireJUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free
- 8mo agoDYAIDyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)GlobeNewswireJUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing
- 8mo agoDYAIDyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development MilestoneGlobeNewswireJUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing
- 8mo agoDYAIDyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human AlbuminGlobeNewswireJUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing
- 10mo agoDYAIDyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial MarketsGlobeNewswireJUPITER, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free
- 11mo agoDYAIDyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic's Recombinant Growth Factors and Media ProteinsGlobeNewswireJUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life
- 11mo agoDYAIDyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition MarketsGlobeNewswireJUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic"), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes
- 12mo agoDYAIDyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic ProgressGlobeNewswireCompleted strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relationsAdvanced multiple
- 1y agoDYAIDyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS GenomicsGlobeNewswireJUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered,
- 1y agoDYAIDyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025GlobeNewswireJUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the
- 1y agoDYAIDyadic Applied BioSolutions Announces Milestone Achievements and Recent Company DevelopmentsGlobeNewswireJUPITER, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing
- 1y agoDYAIDyadic to Present at Investor Conferences and BPI EastGlobeNewswireJUPITER, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on
- 1y agoDYAIDyadic International, Inc. (DYAI) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoDYAIDyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company ProgressGlobeNewswireCompleted Strategic Leadership and Operational Transformation from R&D to Commercial OperationsRebranded as Dyadic Applied BioSolutions to Reflect Our New Operational PrioritiesFull Redesign of Corporate Website to
- 1y agoDYAIDyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025GlobeNewswireJUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of
- 1y agoDYAIUPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common StockGlobeNewswireJUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision
- 1y agoDYAIDyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common StockGlobeNewswireJUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision
- 1y agoDYAIDyadic International, Inc. Announces Proposed Public Offering of Common StockGlobeNewswireJUPITER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision
- 1y agoDYAIDyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutionsBusiness WireReflects the Company's strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms Dyadic International, Inc. ("Dyadic")
- 1y agoDYAIDyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial ApplicationsGlobeNewswireRapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyadic is well
- 1y agoDYAIDyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company ProgressGlobeNewswireExpanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial
- 1y agoDYAIDyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025GlobeNewswireJUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of
- 1y agoDYAIDyadic to Present at World Vaccine Congress | WashingtonGlobeNewswireJUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company that utilizes its microbial production platforms to
- 1y agoDYAIDyadic Reports 2024 Year-End Financial Results and Business UpdatesGlobeNewswireStrong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform
- 1y agoDYAIDyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based VaccinesGlobeNewswireJUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of
- 1y agoDYAIDyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025GlobeNewswireJUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of
- 1y agoDYAIDyadic to Attend Multiple Industry Events in MarchGlobeNewswireJUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of
- 1y agoDYAIDyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireJUPITER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of
- 1y agoDYAIDyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform TechnologyGlobeNewswireJUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI), a global biotechnology company, announced today that it has been awarded a $3 million grant from the Gates Foundation for the